Suppr超能文献

与 ACMG SF v2.0 相比,ClinSeq 队列中 ACMG SF v3.0 基因列表使可检出变异的比例提高了 22%。

The ACMG SF v3.0 gene list increases returnable variant detection by 22% when compared with v2.0 in the ClinSeq cohort.

机构信息

Center for Precision Health Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.

Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD; American College of Medical Genetics and Genomics, Bethesda, MD.

出版信息

Genet Med. 2022 Mar;24(3):736-743. doi: 10.1016/j.gim.2021.11.012. Epub 2021 Nov 18.

Abstract

PURPOSE

The American College of Medical Genetics and Genomics (ACMG) recommends the return of pathogenic and likely pathogenic (P/LP) secondary findings from exome and genome sequencing. The latest version (ACMG secondary finding [SF] v3.0) includes 14 additional genes. We interrogated the ClinSeq cohort for variants in these genes to determine the additional yield in unselected individuals.

METHODS

Exome data from 1473 individuals (60% White, 34% African American or Black, 6% other) were analyzed. We restricted our analyses to coding variants; +1,+2,-1, and -2 splice site variants; and the pathogenic GAA variant, NM_000152.5:c.-32-13T>G. Variants were assessed with slightly modified ACMG/Association of Molecular Pathology guidelines.

RESULTS

A total of 25 P/LP variants were identified. In total, 7 individuals had P/LP variants in genes recommended for return of heterozygous variants, namely HNF1A (1), PALB2 (3), TMEM127 (1), and TTN (2). In total, 4 individuals had a homozygous variant in a gene recommended for biallelic variant return, namely HFE, NM_000410.3(HFE):c.845G>A p.Cys282Tyr. A total of 17 P/LP variants were identified in the heterozygous state in genes recommended only for biallelic variant reporting and were not returned. The frequency of returnable P/LP variants did not significantly differ by race.

CONCLUSION

Using the ACMG SF v3.0, the returnable P/LP variant frequency increased in the ClinSeq cohort by 22%, from 3.4% (n = 50, ACMG SF v2.0) to 4.1% (n = 61, ACMG SF v3.0).

摘要

目的

美国医学遗传学与基因组学学会(ACMG)建议从外显子组和基因组测序中返回致病性和可能致病性(P/LP)的二级发现。最新版本(ACMG 二级发现 [SF] v3.0)包括另外 14 个基因。我们在 ClinSeq 队列中检测了这些基因中的变异,以确定在未选择的个体中额外的检出率。

方法

对 1473 名个体(60%为白人,34%为非裔美国人或黑人,6%为其他种族)的外显子组数据进行了分析。我们将分析仅限于编码变异;+1、+2、-1 和-2 剪接位点变异;以及致病性 GAA 变异,NM_000152.5:c.-32-13T>G。使用稍作修改的 ACMG/分子病理学协会指南评估了变异。

结果

共鉴定出 25 个 P/LP 变异。共有 7 名个体在建议报告杂合变异的基因中携带 P/LP 变异,即 HNF1A(1)、PALB2(3)、TMEM127(1)和 TTN(2)。共有 4 名个体在建议报告双等位基因变异的基因中携带纯合变异,即 HFE,NM_000410.3(HFE):c.845G>A p.Cys282Tyr。共有 17 个 P/LP 变异在仅建议报告双等位基因变异的基因中以杂合状态被检出,但未被报告。可报告的 P/LP 变异的检出率在不同种族之间没有显著差异。

结论

使用 ACMG SF v3.0,ClinSeq 队列中可报告的 P/LP 变异频率增加了 22%,从 ACMG SF v2.0 的 3.4%(n=50)增加到 ACMG SF v3.0 的 4.1%(n=61)。

相似文献

5
The rate of secondary genomic findings in the Saudi population.沙特人口中的二级基因组发现率。
Am J Med Genet A. 2022 Jan;188(1):83-88. doi: 10.1002/ajmg.a.62491. Epub 2021 Sep 13.

本文引用的文献

2
Management of Secondary Genomic Findings.二级遗传检测结果的管理。
Am J Hum Genet. 2020 Jul 2;107(1):3-14. doi: 10.1016/j.ajhg.2020.05.002.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验